Background
Renal cell carcinoma (RCC) is represents 80–90% of adult kidney cancers. RCC incidence varies geographically, with the highest incidence being documented in developed countries [
1]. Based on recent guidelines, the most efficacious treatment for early-stage clear cell renal cell carcinoma (ccRCC) is surgery and targeted therapy [
2]. Unfortunately, the major cause of death for most ccRCC patients is the metastasis and recurrence of tumor cells [
3]. Several new biomarkers have been explored to diagnose and predict the occurrence and development of ccRCC [
4‐
6].
Chromosomal instability, leading to aneuploidy, is one of the hallmarks of human cancers [
7]. Ubiquitin-specific protease (USP)44 is located at 12q22 and encodes a 712-kD amino acid. USP44 is a member of a family of deubiquitinating enzymes and has an important role in human cancers [
8]. USP44 regulates the separation and positioning of centrosomes, and the geometry of mitotic spindles [
9]. USP44 can stabilize the protein expression of protectin in the cycle of healthy cells until all the chromosomes match correctly with spindle fibers and prevent immature mitosis. By inhibiting USP44 expression in mice, the proportion of aneuploid cells and chromosomal instability can be increased significantly, making them more prone to malignant transformation [
10,
11]. However, Zou and colleagues showed that USP44 overexpression promotes the malignancy of glioma [
12].
However, the function and mechanism of action of USP44 in ccRCC have not been clarified, a knowledge gap we aimed to fill in the present study.
Methods
Reagents
Antibodies against Flag (catalog number: M185-3 L) and β-actin (M177–3) were purchased from Medical Biological Laboratories (Nagoya, Japan). Antibodies against matrix metalloproteinase (MMP)9 (A0289) were obtained from ABclonal (Woburn, MA, USA). Antibodies against P21 (2947), cyclin D1 (2978), c-Jun N-terminal kinase (JNK; 9252), phosphorylated (p)-JNK (4668), protein kinase B (AKT; 4691), p-AKT (4060), p38 (9212), p-p38 (4511), extracellular signal-regulated kinase (ERK; 4695) and p-ERK (4370) were purchased from Cell Signaling Technology (Danvers, MA, USA).
The JNK inhibitor JNK-IN-8 (HY-13319, MCE, USA) was dissolved in dimethyl sulfoxide (DMSO) and diluted into a 0.5-μM working solution with complete culture medium, and the same amount of DMSO was set as the control.
Bioinformatics analysis was undertaken in accordance with the work of Jiangqiao and collaborators [
13]. ccRCC’s gene sequence tertiary count data samples and clinical information are obtained through TCGA data portal. DESeq2 within the R Project for Statistical Computing (Vienna, Austria) was used to standardize counting data and analyze differentially expressed genes between cancer samples and normal samples. Standardized data were used primarily to analyze the visual expression, stage, grade and survival correlation of USP44 in ccRCC and adjacent non-cancerous tissues. According to USP44 expression, clinical samples of ccRCC were divided into two groups for analyses.
Kaplan–Meier survival curves were used to show the differences in overall survival between patients with high expression of USP44 and cases with low expression of USP44. Simultaneously, we calculated the correlation between USP44 expression and the age, sex, tumor stage and tumor grade of the patient through T-text, and the obtained data were visualized through ggplot2 within the R Project for Statistical Computing.
Cells
The human ccRCC line 786-O (CRL-1932) was purchased from BeNa Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; C11995500BT; Billings, MT, USA) [
14]. Caki-1 (a cell line of human ccRCC that metastasizes to the skin) was purchased from the Chinese Academy of Sciences Cell Bank (TCHu135; Beijing, China) and was cultured in McCoy’s 5A culture medium (L630; Basal Media, Saint Louis, MO, USA) [
15]. Then, 10% fetal bovine serum (FBS; F05–001-B160216; One Biotechnology, Sarasota, FL, USA), penicillin (100 U/mL) and streptomycin (100 μg/mL) were added to DMEM and McCoy’s 5A. 786-O cells and Caki-1 cells were cultured in a humidified environment at 37 °C containing 5% carbon dioxide.
Lentivirus of overexpressed USP44, and construction and production of short hairpin (sh)RNA USP44 lentivirus
An overexpressed vector with a flag tag and shRNA vectors of the USP44 (homo) gene were designed and constructed according the method described by Jiangqiao and colleagues [
13]. The gene registration number is NM_001347937.1. pHAGE-3xflag was used as the carrier. The primers were h-USP44-NF, AAACGATTCAGGTGGTCAGG, h-USP44-NR, and AGTGTACCCAGAACCCTCCT. The sequence of pLKO.1-h-USP44-shRNA1 was CGGATGATGAACTTGTGCAAT. The sequence of pLKO.1-h-USP44-shRNA2 was GCACAGGAGAAGGATACTAAT.
Cell counting kit (CCK)8 assay
Cell viability was examined using a CCK-8 kit following manufacturer (44,786; Dojindo, Tokyo, Japan) protocols [
13]. 786-O cells and Caki-1 cells were inoculated in 96-well plates (167,008; Thermo Scientific, Waltham, MA, USA). After cells had adhered to the plate, they were cultured further for 0, 12, 24, 36, 48, and 60 h, respectively. CCK8 reagents (10 μL) were added and absorbance at 450 nm measured.
5-bromo-2′-deoxyuridine (BrdU) experiment
The BrdU experiment was undertaken according to manufacturer (11,647,229,001; Roche, Basel, Switzerland) instructions [
13]. 786-O cells and Caki-1 cells were inoculated in 96-well plates. After 24 h and 48 h, the BrdU experiment was carried out.
Wound-healing test
786-O cells and Caki-1 cells were inoculated into six-well plates (140,675; Thermo Scientific) at 3 × 105 cells per well and incubated overnight. After that, the original culture medium was replaced with DMEM containing mitomycin (10 μg/mL). Then, cells were cultured for 12 h. Cells were wounded with a pipette tip and photographs taken immediately (0 h) as well as 6 h and 12 h after wounding. Then, the Cell Migration Index was calculated using the following formula:
Cell Migration Index = (wound width at 0 h – wound width at 6 h or 12 h) × 100/wound width at 0 h.
Cell-migration assay
Healthy 786-O cells and Caki-1 cells were resuspended in DMEM or McCoy’s 5A. Then, they were plated at 3 × 104 cells/well (786-O) or 5 × 104 cells/well (Caki-1) in the upper compartment of a Transwell™ chamber (3421; Corning, Corning, NY, USA). Meanwhile, DMEM containing 600 μL of 2% FBS or 600 μL of 10% FBS was added to the lower chamber, respectively. Cells were cultured for 2 h or 3 h (786-O) or 10 h or 24 h (Caki-1) with phosphate-buffered saline. Then, 600 μL of 4% paraformaldehyde solution was used to fix cells for 15 min at room temperature, and 600 μL of 0.1% crystal violet (548–62-9; Xinkang,Hubei) was used to stain cells for 2 h at 37 °C. Images were acquired under a microscope. The number of positively stained cells reflected the cell-migration ability.
Western blotting
Proteins were extracted from 786-O cells and Caki-1 cells according to standard protocols. Meanwhile, protease inhibitors (04693132001; Roche) and phosphatase inhibitors (4,906,837,001; Roche) were added. Protein concentrations were determined using a Bicinchoninic Acid Protein Assay kit (23,225; Thermo Fisher Scientific). Briefly, we separated protein samples by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 12.5% gels, and then transferred them to nitrocellulose membranes. We blocked the nitrocellulose membranes using 5% nonfat dry milk in TBS-T buffer and incubated them overnight with primary antibody at 4 °C. After rinsing the blots extensively with TBS-T buffer, incubation with secondary antibodies for 1 h was undertaken. We applied a ChemiDoc™ XRS+ gel-imaging system (Bio-Rad Laboratories, Hercules, CA, USA) to detect the target bands.
Reverse transcription-polymerase chain reaction (RT-PCR)
The total mRNA of 786-O and Caki-1 cell lines was extracted with TRIzol® Reagent (15596–026; Invitrogen, Carlsbad, CA, USA). Then, total RNA was reverse-transcribed into complementary (c)DNA using a Transcriptor First Strand cDNA Synthesis kit (04896866001; Roche) according to manufacturer instructions. SYBR® Green (04887352001; Roche) was used to quantify the PCR-amplification products. mRNA expression of target genes was normalized to that of β-actin expression. All the primer information is in Table
1.
Table 1Primers for qPCR detection
USP44 | AAACGATTCAGGTGGTCAGG | AGTGTACCCAGAACCCTCCT |
P21 | TGGAGACTCTCAGGGTCGAAA | TTCCTCTTGGAGAAGATCAGCC |
CyclinD1 | CAGATCATCCGCAAACACGC | AGGCGGTAGTAGGACAGGAA |
MMP2 | CCGTCGCCCATCATCAAGTT | CCGCATGGTCTCGATGGTAT |
MMP9 | TTTGAGTCCGGTGGACGATG | TTGTCGGCGATAAGGAAGGG |
β-ACTIN | CATGTACGTTGCTATCCAGGC | CTCCTTAATGTCACGCACGAT |
Statistical analyses
Data are the mean ± standard error. We used SPSS v19.0 (IBM, Armonk, NY, USA) for statistical analyses. The Student’s t-test was used to analyze all data. P < 0.05 was considered significant.
Discussion
Several studies have demonstrated that the molecular mechanism of ccRCC is closely related to apoptosis, autophagy, hypoxia metabolism and immune imbalance [
23]. However, the mechanism of pathogenesis and metastasis of ccRCC have not been elucidated.
The spindle assembly checkpoint (SAC) is an important mechanism to ensure mitosis. An abnormality of the SAC is a key step in the development of aneuploidy and even tumors. Holland and colleagues reported that the important regulatory proteins of the SAC deubiquitinase USP44 were closely associated with tumors [
24].
We explored the role of USP44 as a tumor marker based on information from the TCGA Data Portal and GEO 102010 database. Results showed that USP44 had low expression in tumor tissues and correlated with the pathologic stage and grade of tumors. Patients with high USP44 expression showed good survival benefits. These results suggest that USP44 may be a good biomarker to predict ccRCC progression.
Some studies have suggested that USP44 overexpression promotes tumor development, whereas other studies have indicated that USP44 inhibits proliferation of tumor cells [
10,
11,
25,
26]. Thus, we examined the effect of USP44 on ccRCC proliferation. Using 786-O cells and Caki-1 cells, we showed that USP44 overexpression inhibited proliferation of these two cell lines. The genes associated with proliferation of these two cell lines were also regulated by USP44 overexpression.
The metastatic potential of ccRCC is the main factor leading to the death of affected patients [
27]. Treatment of metastatic ccRCC has changed considerably over recent years [
28]. The US Food and Drug Administration has approved agents to treat metastatic ccRCC, including immunotherapeutic drugs, antiangiogenic agents, and mammalian target of rapamycin (mTOR) inhibitors [
1,
29]. Nevertheless, even with these treatments, many patients with metastatic ccRCC have very short survival. We demonstrated that USP44 overexpression inhibited migration of tumor cells through wound-healing and cell-migration experiments. To avoid the effect of cell proliferation on cell migration, mitomycin was administered before wound-healing experiments.
The MMP family are involved in breakdown of the extracellular matrix in health and disease (e.g., metastasis) [
20]. MMP2 and MM9 are closely related to the invasion and metastasis of several types of tumor cells [
30]. Our data showed that USP44 overexpression in 786-O cells and Caki-1 cells was a reminder that ccRCC metastasis was related to expression of MMP2 and MMP9. Based on the results from Caki-1 cells with USP44 silencing by shRNAs, we demonstrated that USP44 inhibits ccRCC progression in reverse.
Whether a deubiquitinating enzyme has a role in promoting or inhibiting cancer is closely related to the function of its substrate protein [
31]. Substrate molecules regulate several tumor-associated signaling pathways: p53, nuclear factor-kappa B, Wnt, transforming growth factor-β, and histone epigenetic modifications. These signaling pathways interact with each other. Upregulation of USP expression in tumor cells often suggests that its substrate protein can promote the malignant progression of cancer cells [
32]. Downregulated expression of a USP suggests that its substrate is usually a tumor suppressor. Each USP has multiple substrates, and the same substrates may be regulated by multiple USPs [
33]. Therefore, the regulatory network of a USP on a tumor-cell signaling pathway is extremely complex.
PI3K/AKT is a serine/threonine protein kinase involved in tumorigenesis (including ccRCC) [
34]. If cells are stimulated by extracellular signals, PI3K activates AKT, and the latter further activates its downstream factor mTOR. The MAPK signaling pathway has crucial roles in the occurrence, development, treatment and prognosis of malignant tumors [
35]. The downstream signaling pathway includes JNK, ERK and p38, which are associated with the growth and proliferation of tumor cells [
36]. AKT-JNK/p38/ERK has been shown to be involved in the progression of lung cancer and pancreatic cancer [
34,
37]. We measured the protein activity of JNK, AKT, ERK and p38. We found that USP44 inhibited the JNK pathway but not the AKT, ERK or p38 pathways. Rescue experiments showed that silencing USP44 expression to promote the proliferation and migration of tumor cells could be blocked by a JNK inhibitor. JNK activation in USP44 knockdown could have been a result of stress-response activation due to chromosome mis-segregation, as reported by Kumar and colleagues [
38]. The ubiquitin-proteasome system regulates oncogenic factors post-transcriptionally at the epigenetic level. Studies have shown that important tumor-related factors, such as the epidermal growth factor receptor, sarbox-2, c-myc, and McL-1, are regulated by USPs. However, little is known about the catalytic substrates of USP44. In current study, overexpression of USP44 enhanced the malignancy of glioma by stabilizing tumor-promoter securing [
12]. USP44 can induce the genesis of prostate cancer cells partly by stabilizing EZH2 [
39]. Therefore, further studies are needed to ascertain whether USPP44 regulates a promoter or tumor suppressor in ccRCC.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.